Boucekastichus

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Retrieved on: 
Monday, September 20, 2021
Therapy, Bossard Holding AG, Pembrolizumab, Carboplatin, Hoffmann-La Roche, OTC, City of Hope, Conference, Ageing, Boucekastichus, Squamous cell carcinoma, ONC, Wilms' tumor, Light, City, Breast cancer, Pfizer UK, Optimism, Roche, Disease, Technology, Pfizer, Etoposide, Maintenance, Radiation, Survival, Lead, COTA, BMS, NYSE, Data visualization, Oncology, Neoplasm, Partnership, CURE, Oncolytics Biotech, Patient, NASDAQ, FDA, Cancer, MRK, Bristol Myers Squibb, Kidney cancer, Pelareorep, Trastuzumab, Large-cell lung carcinoma, Risk, BMY, HCP, Trastuzumab emtansine, TSX, News, Immunotherapy, NHS, CO, International Conference on Population and Development, PFE, Pharmaceutical industry, Medical imaging

VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ -- USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer treatments can and should be moving forward faster. However, in many ways, 2021 has witnessed several major developments that continue to provide optimism within the oncology field, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC),Roche Holding AG (OTC: RHHBY), Merck &. Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Pfizer Inc. (NYSE: PFE).

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Retrieved on: 
Monday, September 20, 2021
Therapy, Bossard Holding AG, Pembrolizumab, Carboplatin, Hoffmann-La Roche, OTC, City of Hope, Conference, Ageing, Boucekastichus, Squamous cell carcinoma, ONC, Wilms' tumor, Light, City, Breast cancer, Pfizer UK, Optimism, Roche, Disease, Technology, Pfizer, Etoposide, Maintenance, Radiation, Survival, Lead, COTA, BMS, NYSE, Data visualization, Oncology, Neoplasm, Partnership, CURE, Oncolytics Biotech, Patient, NASDAQ, FDA, Cancer, MRK, Bristol Myers Squibb, Kidney cancer, Pelareorep, Trastuzumab, Large-cell lung carcinoma, Risk, BMY, HCP, Trastuzumab emtansine, TSX, News, Immunotherapy, NHS, CO, International Conference on Population and Development, PFE, Pharmaceutical industry, Medical imaging

In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.